References
- Chen, C., and R. A. Beckman. 2009. Optimal cost-effective Go-No Go decisions in late-stage oncology drug development. Statistics in Biopharmaceutical Research 1 (2):159–169. doi:10.1198/sbr.2009.0027.
- Deng, Q., and X. Lu. 2018. Choosing timing and boundary for futility analysis based on cost-effectiveness assessment. Statistics in Biopharmaceutical Research 10 (2):104–111. doi:10.1080/19466315.2018.1456483.
- Fu, H., and D. Manner. 2010. Bayesian adaptive dose-finding studies with delayed responses. Journal of Biopharmaceutical Statistics 20 (5):1055–1070. doi:10.1080/10543400903315740.
- Lee, J. J., and D. D. Liu. 2008. A predictive probability design for phase II cancer clinical trials. Clinical Trials 5 (2):93–106. doi:10.1177/1740774508089279.
- Li, W., M. -H. Chen, X. Wangy, and D. K. Dey. 2018. Bayesian design of Non-inferiority clinical trials via the Bayes factor. Statistics in Biosciences 10 (2):439–459. doi:10.1007/s12561-017-9200-5.
- Saville, B., J. Connor, G. Ayers, and J. Alvarez. 2014. The utility of Bayesian predictive probabilities for interim monitoring of clinical trials. Clinical Trials 11 (4):485–493. doi:10.1177/1740774514531352.
- Thall, P. F., and R. Simon. 1994. Practical Bayesian guidelines for phase IIB clinical trials. Biometrics 50 (2):337–349. doi:10.2307/2533377.
- Togo, K., and M. Iwasaki. 2013. Optimal timing for interim analyses in clinical trials. Journal of Biopharmaceutical Statistics 23 (5):1067–1080. doi:10.1080/10543406.2013.813522.
- U.S. FDA. 2020. “Guidance for the use of bayesian statistics in medical device clinical trials.” U.S. Food and Drug Administration. Available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-use-bayesian-statistics-medical-device-clinical-trials.
- Wu, X., Y. Xu, and B. P. Carlin. 2020. Optimizing interim analysis timing for Bayesian adaptive commensurate designs. Statistics in Medicine 39 (4):424–437. doi:10.1002/sim.8414.